Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study

Luis Felipe Reyes, Srinivas Murthy, Esteban Garcia-Gallo, Mike Irvine, Laura Merson, Ignacio Martin-Loeches, Jordi Rello, Fabio S. Taccone, Robert A. Fowler, Annemarie B. Docherty, Christiana Kartsonaki, Irene Aragao, Peter W. Barrett, Abigail Beane, Aidan Burrell, Matthew Pellan Cheng, Michael D. Christian, Jose Pedro Cidade, Barbara Wanjiru Citarella, Christl A. Donnelly, Susana M. Fernandes, Craig French, Rashan Haniffa, Ewen M. Harrison, Antonio Ying Wai Ho, Mark Joseph, Irfan Khan, Michelle E. Kho, Anders Benjamin Kildal, Demetrios Kutsogiannis, François Lamontagne, Todd C. Lee, Gianluigi Li Bassi, Jose Wagner Lopez Revilla, Catherine Marquis, Jonathan Millar, Raul Neto, Alistair Nichol, Rachael Parke, Rui Pereira, Sergio Poli, Pedro Povoа, Kollengode Ramanathan, Oleksa Rewa, Jordi Riera, Sally Shrapnel, Maria Joao Silva, Andrew Udy, Timothy Uyeki, Steve A. Webb, Evert-Jan Wils, Amanda Rojek, Piero L. Olliaro, on behalf of the ISARIC Clinical Characterisation Group

1Universidad de La Sabana, Chía, Colombia. 2Nuffield Dept of Medicine, University of Oxford, Oxford, UK. 3British Columbia Children's Hospital, Vancouver, BC, Canada. 4British Columbia Centre for Disease Control, Vancouver, BC, Canada. 5Intensive Care Medicine, St James’s Hospital, Dublin, Ireland. 6Vall d’Hebron Institute of Research, Barcelona, Spain. 7Erasmse Hospital, Université Libre de Bruxelles, Brussels, Belgium. 8Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 9Centro Hospitalar Universitario do Porto, Porto, Portugal. 10Piedmont Atlanta Hospital, Atlanta, GA, USA. 11Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand. 12Monash University, Melbourne, Australia. 13McGill University, Hamilton, ON, Canada. 14Bart’s NHS Health Trust, London, UK. 15Hospital São Francisco Xavier, Lisbon, Portugal. 16Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. 17Western Health, Melbourne, Australia. 18Carilion Clinic, Roanoke, VA, USA. 19Presbyterian Hospital Services, Albuquerque, NM, USA. 20University Hospital of North Norway, Tromsø, Norway. 21The University of Alberta, School of Medicine and Dentistry, Edmonton, AB, Canada. 22Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada. 23University of Queensland, Brisbane, Australia. 24Instituto Nacional del Niño San Borja, Lima, Peru. 25Roslin Institute, University of Edinburgh, Edinburgh, UK. 26Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. 27St Vincent’s University Hospital, Dublin, Ireland. 28Auckland City Hospital, Auckland, New Zealand. 29Hospital Curry Cabral, Lisbon, Portugal. 30Mount Sinai Medical Center, Miami, FL, USA. 31National University of Singapore, Singapore, Singapore. 32Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. 33Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands.

Corresponding author: Luis Felipe Reyes (luis.reyes5@unisabana.edu.co)

Countries and hospitals need to identify strategies to increase their ICU capacity (i.e. trained personnel, ICU beds and monitoring systems) to treat patients presenting to the hospital with severe COVID19 rather than provide such care outside of the ICU. https://bit.ly/3xh9A6M

Cite this article as: Reyes LF, Murthy S, Garcia-Gallo E, et al. Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. ERJ Open Res 2022; 8: 00552-2021 [DOI: 10.1183/23120541.00552-2021].

Due to the large number of patients with severe coronavirus disease 2019 (COVID-19), many were treated outside the traditional walls of the intensive care unit (ICU), and in many cases, by personnel who were...
not trained in critical care. The clinical characteristics and the relative impact of caring for severe COVID-19 patients outside the ICU is unknown. This was a multinational, multicentre, prospective cohort study embedded in the International Severe Acute Respiratory and Emerging Infection Consortium World Health Organization COVID-19 platform. Severe COVID-19 patients were identified as those admitted to an ICU and/or those treated with one of the following treatments: invasive or noninvasive mechanical ventilation, high-flow nasal cannula, inotropes or vasopressors. A logistic generalised additive model was used to compare clinical outcomes among patients admitted or not to the ICU. A total of 40,440 patients from 43 countries and six continents were included in this analysis. Severe COVID-19 patients were frequently male (62.9%), older adults (median (interquartile range (IQR), 67 (55–78) years), and with at least one comorbidity (63.2%). The overall median (IQR) length of hospital stay was 10 (5–19) days and was longer in patients admitted to an ICU than in those who were cared for outside the ICU (12 (6–23) days versus 8 (4–15) days, p<0.0001). The 28-day fatality ratio was lower in ICU-admitted patients (30.7% (5797 out of 18,831) versus 39.0% (7532 out of 19,295), p<0.0001). Patients admitted to an ICU had a significantly lower probability of death than those who were not (adjusted OR 0.70, 95% CI 0.65–0.75; p<0.0001).

Patients with severe COVID-19 admitted to an ICU had significantly lower 28-day fatality ratio than those cared for outside an ICU.

**Background**

The clinical presentation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection varies from asymptomatic to severe respiratory failure [1]. Severely ill patients may require advanced respiratory support (e.g. invasive or noninvasive mechanical ventilation or high-flow nasal cannula (HFNC)) or extra-respiratory support (e.g. vasopressors, inotropes or renal replacement therapy) [2]. Severe coronavirus disease 2019 (COVID-19), defined as requiring intensive care unit (ICU) admission or advanced ventilatory support, occurs in 15–30% of hospitalised individuals, with in-hospital fatality ratios ranging from 30% to 70%, depending on various factors including patients’ age, comorbidities and access to medical interventions [3, 4]. High-quality supportive care remains the standard of care for these patients [5, 6].

During the SARS-CoV-2 pandemic, many international healthcare systems became overwhelmed, requiring medical interventions traditionally restricted to delivery in an ICU by specially trained personnel to be delivered in other hospital areas, sometimes by healthcare workers without equivalent training [7]. Thus, invasive and noninvasive mechanical ventilation, HFNCs and treatment with inotropes or vasopressors, have been used outside of the ICU due to the acute surge in cases and lack of ICU capacity [8]. Several strategies have been proposed to rapidly train non-ICU personnel and to optimise resources during the pandemic [9]. However, the impact of these strategies is unknown.

Most studies describing the clinical characteristics and outcomes of COVID-19 patients admitted to the ICU are limited to a few centres within a single country and have not evaluated the impact of ICU-level treatment on clinical outcomes [1, 10, 11]. Moreover, available studies have not evaluated the outcomes of severely ill patients cared for outside the ICU environment [1, 10, 11]. Moreover, there is a growing concern about whether available data characterising patients with severe COVID-19 are generalisable to other regions of the world and whether severe COVID-19 patients can safely be cared for outside of an ICU [12]. Here, we describe a global population of patients with severe COVID-19, both those with and without ICU admissions during their hospital stay. In addition, we describe outcomes in patients with severe COVID-19 inside and outside the ICU to determine the potential impact of ICU admission.

**Methods**

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)-World Health Organization (WHO) Clinical Characterisation Protocol for Severe Emerging Infections provided a framework for prospective observational data collection on hospitalised patients. The study information is available in the supplementary material and the protocol, case report forms and consent forms are available on the ISARIC website (https://isaric.tghn.org). This is a standardised protocol for investigating severe acute infections of pathogens of public health interest with tiered data collection tailored to a range of resource settings. Investigators from 43 countries collected prospective data using the ISARIC case report form built on Research Electronic Data Capture (REDCap, version 8.11.11; Vanderbilt University, Nashville, TN, USA) hosted by the University of Oxford (Oxford, UK). Other investigators collected data on a variety of locally hosted data systems and submitted data for centralised mapping to the ISARIC dataset. All investigators retain full rights to their data.

This observational study required no change to clinical management and permitted patient enrolment in other research projects. The ISARIC-WHO Clinical Characterisation Protocol was approved by the WHO...
ethics review committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements.

**Study population**
Hospital-admitted patients included in the ISARIC database between 17 January and 31 December 2020; this analysis was limited to those with laboratory-confirmed SARS-CoV-2 infection detected by reverse-transcriptase (RT)-PCR in a respiratory sample analysed according to the sites’ local diagnostic methods and protocols and classified as severe COVID-19. We used a modified WHO severity criterion [5] to categorise severe COVID-19 using the following criteria: patients treated with invasive or noninvasive mechanical ventilation, those treated with HFNC, and/or patients treated with vasopressors or inotropes and/or patients treated within the ICU. Patients in whom >30% of the required clinical data variables were missing were excluded from the analysis.

**Outcomes**
The primary outcome of this analysis was 28-day fatality ratio (from hospital admission date). The secondary outcomes were 90-day fatality ratio and hospital length of stay (LOS).

**Variables and measurement**
Variables used in this analysis were age, sex, ethnicity (i.e. White, Black, Latino, Asian, Arab, other), symptoms, comorbidities, vital signs on admission, systemic complications, date of hospital admission, date of ICU admission, date of death, the requirement of advanced ventilatory support, treatment with vasopressors or inotropes, country of recruitment and its income classification according to the World Bank (https://data.worldbank.org/country). All the variables are listed in the study protocol and the supplementary material. To study fatality ratios, only patients with a reported date of death were classified as dead. Patients that were still admitted at the point of data extraction were not included in the denominator to calculate the fatality ratio or other clinical outcomes. Only patients with a reported hospital discharge were included in calculating the hospital LOS. All study variables were pre-defined in the ISARIC study protocol and case report form completion guide available online (https://isaric.tghn.org/research/covid-19-clinical-research-resources/covid-19-crf). The number of COVID-19 cases per million were obtained from the website Our World in Data [13].

**Study definitions**
The complete definitions of all variables were pre-determined in the study protocol and are available in the supplementary material. However, some definitions are provided here.

ICU admission: patients admitted to an intensive care, intensive therapy, intermediate care or high dependency unit. This variable was collected independent of treatments received and was reported by each centre.

High-flow nasal cannula: respiratory support continuously applied through large-bore nasal prongs using a gas flow heated and humidified at initial flow greater of 20 L-min⁻¹ (or up to 80 L-min⁻¹) and fraction of inspiratory oxygen of up to 1.0.

**Statistical methods**
Data were converted to Study Data Tabulation Model standards (version 1.7; Clinical Data Interchange Standards Consortium, Austin, TX, USA) to integrate data collected on locally hosted databases with data collected on the ISARIC database. A bivariate analysis was initially carried out to compare the quantitative variables according to their distribution by other factors. If data were normally distributed, the t-test was applied for independent samples; if the variable data were not normally distributed, the Mann–Whitney U-test was used. Categorical variables were compared by a Chi-squared test. Variables were analysed by age, sex, date of hospital admission and ICU admission. A logistic generalised additive model (GAM) was fitted to assess the association of being admitted to the ICU with 28-day fatality ratio, adjusting for demographics (i.e. sex and number of comorbidities); age, treated as a nonlinear continuous measure using a cubic spline; physiological variables on admission (i.e. heart rate, respiratory rate and systolic and diastolic blood pressure); advanced ventilatory support (i.e. HFNC, noninvasive mechanical ventilation or invasive mechanical ventilation); treatment with vasopressors or inotropes; the development of acute respiratory distress syndrome (ARDS) during hospital stay; month of admission; country income classification; and new cases per million people per country at the moment of hospital admission.

To further assess the nonlinear associations of age, calendar time and per-capita number of COVID-19 cases within a country with fatality ratio, a logistic GAM was fitted using 28-day fatality ratio as a
dichotomous outcome. Further nonlinear terms for age, comorbidities, calendar day and COVID-19 cases per million in the affected country were modelled as cubic splines. A sensitivity analysis was constructed using the above GAM and excluding patients enrolled in the United Kingdom (UK) (the majority of patients included in the analysis were registered in this country) to control for the centre effect. A further sensitivity analysis was constructed by excluding all patients identified as admitted to ICU without any other advanced ventilator support or vasopressor. All data processing and statistical analysis were performed using Python version 4.0 with the following data packages: Pandas version 1.2.4, Tidyverse version 1.3.0, Bioconductor version 3.12. In addition, we used R version 4.0.4 and SPSS 27 for Mac.

**Results**

149,504 patients with RT-PCR-confirmed SARS-CoV-2 infection were screened for the study. After applying the enrolment criteria, 40,440 severe COVID-19 patients fulfilled the inclusion criteria and were included in the analysis (figure 1). Patients were enrolled in six continents and 43 countries. The majority of patients were enrolled in high-income countries (88.9%, 35,956 out of 40,440); however, 4,472 patients were enrolled in upper middle-income and lower middle-income countries (figure 2, table 1). Importantly, 85.2% of patients were enrolled in Europe (figure 2, table 1).

**Demographic and clinical characteristics**

Most of the patients were male (62.9%, 25,459 out of 40,440), with a median (interquartile range (IQR)) age of 67 (55–78) years. The race of patients was most frequently recorded as White (53.0%, 21,460 out of 40,440), followed by Asian (7.6%, 3,080 out of 40,440), Black (4.0%, 1,631 out of 40,440) and Latino (1.0%, 425 out of 40,440). At least one comorbidity was reported in 63.2% (25,591 out of 40,440) of patients (table 1); the most frequently identified comorbidity was chronic arterial hypertension (29.5%, 11,910 out of 40,404), followed by chronic cardiac disease (20.2%, 8,161 out of 40,440), chronic pulmonary diseases (12.0%, 4,848 out of 40,440), obesity (11.4%, 4,623 out of 40,440) and chronic kidney disease (10.3%, 4,151 out of 40,440). ICU patients were younger (61 (50–70) years versus 75 (62–84) years, p<0.0001),

---

**FIGURE 1** Study flow chart. ISARIC: International Severe Acute Respiratory and Emerging Infection Consortium; WHO: World Health Organization; COVID-19: coronavirus disease 2019; ICU: intensive care unit.
more frequently male (67.7% (13 571 out of 20 044) versus 58.4% (11 930 out of 20 396), p<0.0001) and had fewer comorbidities (1 (0–2) versus 2 (0–4), p<0.0001) than non-ICU patients (table 1).

Regarding symptoms on the day of hospital admission, the most frequently reported were shortness of breath (59.2%, 23 955 out of 40 440), fever (52.2%, 21 115 out of 40 440), dry cough (52.1%, 21065 out of 40 440) and fatigue/malaise (30.6%, 12 391 out of 40 440). Regarding physiological parameters on hospital admission, the median (IQR) temperature was 37.3°C (36.7–38.2°C); patients were tachycardic (93 (81–108) beats·min\(^{-1}\)) and tachypnoeic (24 (20–28) breaths·min\(^{-1}\)) on admission (table 1). Other differences were observed in the physiological variables between patients admitted and not admitted to the ICU (table 1).

In-hospital treatments and systemic complications
The most frequently administered treatments were systemic antibiotics (87.3%, 35 316 out of 40 440), systemic corticosteroids (28.3%, 11 435 out of 40 440) and antivirals (19.8%, 8025 out of 40 440). Among the whole cohort, 62.9% (25 433 out of 40 440) of patients were treated with HFNC, 38.4% (15 522 out of 40 440) with noninvasive mechanical ventilation and 40.7% (16 542 out of 40 440) were treated with inotropes or vasopressors (table 2, supplementary figures S1 and S2). Invasive mechanical ventilation was more frequently applied in ICU compared to non-ICU patients (59.6% (11 957 out of 20 044) versus 2.5% (505 out of 19 891), p<0.0001); in contrast, non-ICU patients were more frequently treated with HFNC (81.1% (16 542 out of 19 819) versus 44.4% (8891 out of 20 044), p<0.0001) (table 2). Moreover, patients admitted to the ICU were more frequently treated with prone positioning (36.9% (7390 out of 20 044) versus 2.1% (277 out of 20 396), p<0.0001), systemic corticosteroids (38.1% (7627 out of 20 044) versus 18.7% (3808 out of 20 396), p<0.0001) and haemodialysis (14.7% (2953 out of 20 044) versus 1.2% (238 out of 20 396), p<0.0001) than non-ICU patients (table 2).

Systemic complications were reported in the majority of patients (64.4%, 26 068 out of 40 440); 19.6% (7928 out of 28 182) of patients developed ARDS, being more frequent in patients admitted to the ICU (28.7% (5747 out of 20 044) versus 10.5% (2181 out of 20 396), p<0.0001). Moreover, acute kidney injury was documented more frequently in ICU-admitted patients (20.1% (4030 out of 20 044) versus 12.4% (2536 out of 20 396)). Bacterial pneumonia was more frequent in patients admitted to the ICU (12.9% (2591 out of 20 044) versus 10.3% (2104 out of 20 396), p<0.0001). Other systemic complications are reported in table 3.
### TABLE 1
Baseline characteristics of patients with confirmed severe acute respiratory syndrome coronavirus 2 infection who developed severe coronavirus disease 2019 stratified by patients admitted to the intensive care unit (ICU)

| Demographics | All Patients admitted to the ICU | Patients admitted to the ICU | p-value |
|--------------|---------------------------------|-----------------------------|---------|
| Demographics | 40 440                          | 20 044                      | 20 396  |
| Age, median (IQR) | 67 (55–78) | 61 (50–70) | 75 (62–84) | <0.0001 |
| Female, n (%) | 14,939 (36.9) | 6,473 (32.2) | 8,466 (41.5) | <0.0001 |
| Number of comorbidities, median (IQR) | 2.0 (0.0–3.0) | 1.0 (0.0–2.0) | 2.0 (0.0–4.0) | <0.0001 |
| Chronic arterial hypertension | 11,910 (29.5) | 5,712 (28.5) | 6,198 (30.4) | <0.0001 |
| Chronic cardiac disease | 8,611 (20.2) | 2,493 (12.4) | 6,118 (29.7) | <0.0001 |
| Chronic cardiac arrhythmia | 38 (0.1) | 34 (0.2) | 4 (0.0) | <0.0001 |
| Chronic pulmonary disease | 4,648 (12.0) | 1,423 (7.1) | 3,225 (15.8) | <0.0001 |
| Chronic neurological disorder | 2,898 (7.2) | 798 (4.0) | 2,100 (10.3) | <0.0001 |
| Chronic rheumatic disorder | 2,736 (6.8) | 794 (4.0) | 1,942 (9.5) | <0.0001 |
| Chronic kidney disease | 4,151 (10.3) | 1,252 (6.2) | 2,899 (14.2) | <0.0001 |
| Mild liver disease | 413 (1.0) | 187 (0.9) | 226 (1.1) | 0.08 |
| Moderate or severe liver disease | 454 (1.1) | 163 (0.8) | 291 (1.4) | <0.0001 |
| Diabetes mellitus | 9,141 (22.6) | 4,343 (21.7) | 4,798 (23.5) | <0.0001 |
| Chronic haematological disorder | 1,069 (2.6) | 354 (1.8) | 715 (3.5) | <0.0001 |
| Chronic immunosuppressive disorders | 44 (0.1) | 44 (0.2) | 0 (0.0) | <0.0001 |
| Chronic immunosuppressive medication | 537 (1.3) | 194 (1.0) | 343 (1.7) | <0.0001 |
| Cancer | 680 (1.7) | 197 (1.0) | 483 (2.4) | <0.0001 |
| Malignant neoplasm | 2,453 (6.1) | 797 (4.0) | 1,656 (8.1) | <0.0001 |
| Solid organ transplant recipient | 192 (0.5) | 76 (0.4) | 116 (0.6) | 0.006 |
| AIDS/HIV | 178 (0.4) | 123 (0.6) | 55 (0.3) | <0.0001 |
| Asplenia | 46 (0.1) | 45 (0.2) | 1 (0.0) | <0.0001 |
| Dementia | 2,774 (6.9) | 188 (0.9) | 2,586 (12.7) | <0.0001 |
| Obesity | 4,623 (11.4) | 2802 (14.0) | 1,821 (8.9) | <0.0001 |
| Malnutrition | 628 (1.6) | 210 (1.0) | 418 (2.0) | <0.0001 |
| Symptoms on admission, n (%) | | | |
| Fever | 21,115 (52.2) | 10,578 (52.8) | 10,537 (51.7) | 0.02 |
| Abdominal pain | 2,386 (5.9) | 1,143 (5.7) | 1,243 (6.1) | 0.09 |
| Bleeding (haemorrhage) | 463 (1.1) | 173 (0.9) | 290 (1.4) | <0.0001 |
| Fatigue/malaise | 12,391 (30.6) | 6,317 (31.5) | 6,074 (29.8) | <0.0001 |
| Shortness of breath | 23,955 (59.2) | 11,924 (59.5) | 12,031 (59.0) | 0.30 |
| Sore throat | 2,464 (6.1) | 1,619 (8.1) | 845 (4.1) | <0.0001 |
| Dry cough | 21,065 (52.1) | 10,230 (51.0) | 10,835 (53.1) | <0.0001 |
| Cough – productive | 6,693 (16.6) | 3,132 (15.6) | 3,561 (17.5) | <0.0001 |
| Cough – with haemoptysis | 804 (2.0) | 444 (2.2) | 360 (1.8) | 0.001 |
| Wheezing | 2,294 (5.7) | 850 (4.2) | 1,444 (7.1) | <0.0001 |
| Seizures | 352 (0.9) | 148 (0.7) | 204 (1.0) | 0.05 |
| Altered consciousness/confusion | 5,964 (14.7) | 1,759 (8.8) | 4,205 (20.6) | <0.0001 |
| Disturbance or loss of smell (anosmia) | 1,047 (2.6) | 614 (3.1) | 433 (2.1) | <0.0001 |
| Disturbance or loss of taste (ageusia) | 1,275 (3.2) | 631 (3.1) | 644 (3.2) | 0.95 |
| Severe dehydration | 1,614 (4.0) | 538 (2.7) | 1,076 (5.3) | <0.0001 |
| Vomiting/nausea | 5,006 (12.4) | 2,469 (12.3) | 2,537 (12.4) | 0.71 |
| Diarrhoea | 5,335 (13.2) | 2,872 (14.3) | 2,463 (12.1) | <0.0001 |
| Muscle aches (myalgia) | 5,562 (13.8) | 3,397 (16.9) | 2,165 (10.6) | <0.0001 |
| Chest pain | 3,823 (9.5) | 1,951 (9.7) | 1,872 (9.2) | 0.05 |
| Headache | 2,918 (7.2) | 1,747 (8.7) | 1,171 (5.7) | <0.0001 |
| Joint pain (arthralgia) | 1,495 (3.7) | 739 (3.7) | 756 (3.7) | 0.91 |
| Skin ulcers | 419 (1.0) | 77 (0.4) | 342 (1.7) | <0.0001 |
| Lower chest wall indrawing | 528 (1.3) | 334 (1.7) | 194 (1.0) | <0.0001 |
| Skin rash | 304 (0.8) | 140 (0.7) | 164 (0.8) | 0.24 |
| Conjunctivitis | 110 (0.3) | 72 (0.4) | 38 (0.2) | 0.001 |
| Runny nose (rhinorrhoea) | 927 (2.3) | 665 (3.3) | 262 (1.3) | <0.0001 |

Continued
Clinical outcomes
The overall 28-day fatality ratio in our cohort was 34.9% (13,329 out of 38,126), and 37.7% (14,394 out of 38,126) for 90-day fatality ratio (figure 1, table 1, supplementary figure S5). The 28-day fatality ratio was 30.7% (5,797 out of 18,831) in patients admitted to the ICU and 39.0% (7,532 out of 19,295) in patients cared for exclusively outside the ICU. The 90-day fatality ratio was 33.7% (6,358 out of 18,831) in those admitted to the ICU and 41.6% (8,036 out of 19,295) in those cared for outside the ICU (figure 3). The median (IQR) overall hospital LOS was 10 (5–19) days, which was longer in ICU patients (12 (6–23) days versus 8 (4–15) days, p<0.0001) when compared to non-ICU patients (table 1). Finally, the hospital LOS in survivors was 11 (5–21) days, and it was longer in ICU-admitted patients (13 (6–27) days versus 9 (5–17) days, p<0.0001).

A biphasic distribution of the number of cases and deaths was identified, with peaks between April and May 2020 and between October and November 2020 (supplementary figures S3 and S4). Patients aged >65 years were frequently diagnosed with severe COVID-19 and had a higher fatality ratio (supplementary figures S3 and S4). A clear relationship between age and the probability of death was observed (figure 4 and supplementary figure S5). Over the study period, fatality ratio in patients with severe COVID-19 decreased over time, being higher during April and lower by the end of August (figure 4 and supplementary figure S5).

Association of ICU admission with 28-day and 90-day fatality ratios
After adjusting for confounding variables (i.e. age, number of comorbidities, sex, presence of ARDS, treatments (inotropes, vasopressors, HFNC, invasive and noninvasive mechanical ventilation), country’s income classification, number of new cases per day in the relevant country and physiological variables (heart rate, respiratory rate, systolic or diastolic blood pressure, and temperature)) on hospital admission, patients admitted to the ICU had a lower 28-day fatality ratio (OR 0.70, 95% CI 0.65–0.75, p<0.0001)
In addition, patients enrolled later in the pandemic (i.e., after the first peak in May–June 2020) were less likely to die, regardless of ICU admission (OR 0.98, 95% CI 0.96–0.99, p<0.0001). Previously documented risk factors for death, including age, sex, prior comorbidities and ARDS were confirmed in our study (table 4).

To test these results, we performed a sensitivity analysis with ethnicity (supplementary table S3), patient enrolment in the UK, sex and age revealed a similar protective effect of ICU admission on 28-day and 90-day fatality ratios (table 4, figure 4, supplementary figure S5). Then, we performed a supplementary sensitivity analysis to control for centre effect by removing patients enrolled in the UK, finding lower fatality ratios in patients admitted to the ICU (supplementary table S2). Finally, we removed patients admitted to ICU who did not need advanced ventilatory support (n=2716; supplementary figure S1), confirming that patients admitted to the ICU had lower likelihood of dying.

**TABLE 2** Treatments stratified by patients admitted to the intensive care unit (ICU)

| Treatments                          | All Patients admitted to the ICU | p-value |
|-------------------------------------|----------------------------------|---------|
|                                     | Yes | No |         |
| **Patients, n**                     | 40440 | 20044 | 20396 | <0.0001 |
| Invasive mechanical ventilation     | 12462 (30.8) | 11957 (59.6) | 505 (2.5) | <0.0001 |
| Noninvasive mechanical ventilation  | 15522 (38.4) | 9127 (45.5) | 6395 (31.4) | <0.0001 |
| High-flow nasal cannula             | 25433 (62.9) | 8891 (44.4) | 16542 (81.1) | <0.0001 |
| Inotropes or vasopressors           | 16542 (40.7) | 8375 (41.8) | 175 (0.9) | <0.0001 |
| Antibiotics                         | 35316 (87.3) | 17800 (88.8) | 17516 (85.9) | <0.0001 |
| Prone positioning                   | 7825 (19.3) | 7390 (36.9) | 435 (2.1) | <0.0001 |
| Neuraminidase inhibitors            | 231 (0.6) | 118 (0.6) | 113 (0.6) | 0.69 |
| Neuroumuscular blocking agents      | 3647 (9.0) | 3597 (17.9) | 50 (0.2) | <0.0001 |
| Dialysis/haemofiltration            | 3191 (7.9) | 2953 (14.7) | 238 (1.2) | <0.0001 |
| Corticosteroids                     | 11435 (28.3) | 7627 (38.1) | 3808 (18.7) | <0.0001 |
| Antivirals                          | 8025 (19.8) | 5925 (29.6) | 2100 (10.3) | <0.0001 |
| Tracheostomy                        | 2461 (6.1) | 2422 (12.1) | 39 (0.2) | <0.0001 |
| ECMO                                | 706 (1.7) | 706 (3.5) | 0 (0.0) | <0.0001 |
| ACE inhibitors                      | 4399 (10.9) | 1991 (9.9) | 2408 (11.8) | <0.0001 |
| Antifungal                          | 3200 (7.9) | 2384 (11.9) | 816 (4.0) | <0.0001 |
| Angiotensin II receptor blockers    | 2865 (7.1) | 1674 (8.4) | 1195 (5.8) | <0.0001 |
| Therapeutic anticoagulants          | 532 (1.3) | 510 (2.5) | 22 (0.1) | <0.0001 |
| Lopinavir/ritonavir                  | 651 (1.6) | 397 (2.0) | 254 (1.2) | <0.0001 |
| Nonsteroidal anti-inflammatory      | 2317 (5.7) | 1191 (5.9) | 1126 (5.5) | 0.07 |
| Inhaled nitric oxide                | 505 (1.2) | 491 (2.4) | 14 (0.1) | <0.0001 |
| Chloroquine/hydroxychloroquine      | 946 (2.3) | 718 (3.6) | 228 (1.1) | <0.0001 |
| Convalescent plasma                 | 398 (1.0) | 248 (1.2) | 150 (0.7) | <0.0001 |
| Macrolides                          | 83 (0.2) | 66 (0.3) | 17 (0.1) | <0.0001 |
| Dexamethasone                       | 4174 (10.3) | 1992 (9.9) | 2182 (10.7) | 0.01 |
| Interferon-β                       | 131 (0.3) | 118 (0.6) | 13 (0.1) | <0.0001 |
| Oral steroids                       | 311 (0.8) | 275 (1.4) | 36 (0.2) | <0.0001 |
| Remdesivir                          | 2009 (5.0) | 1092 (5.4) | 917 (4.5) | <0.0001 |
| IL-6 inhibitor                      | 122 (0.3) | 90 (0.4) | 32 (0.2) | <0.0001 |
| Tocilizumab                         | 51 (0.1) | 42 (0.2) | 9 (0.0) | <0.0001 |

Data are presented as n (%), unless otherwise stated. ECMO: extracorporeal membrane oxygenation; ACE: angiotensin-converting enzyme; IL: interleukin.

Discussion

This analysis describes the clinical characteristics, symptoms and outcomes from the largest prospective multinational cohort of hospitalised patients with severe COVID-19. Worse clinical outcomes were seen in older, male, obese patients with comorbidities and those who developed ARDS. Fatality ratios in patients hospitalised with severe COVID-19 changed over time, being higher during the initial weeks of the pandemic’s first wave. Finally, we identified that severe COVID-19 patients admitted to ICU had lower 28-day and 90-day fatality ratios, independent of age, disease severity, number of comorbidities, country’s income classification, healthcare system saturation (i.e. number of new cases per day) and treatments received when compared with patients that were cared for outside ICU.
Previous studies have found that ~30% of patients infected with SARS-CoV-2 can develop severe disease requiring admission to an ICU or advanced ventilatory support, such as invasive or noninvasive mechanical ventilation or HFNC [10, 14–17]. Our study found that 32% of patients who required hospital admission developed severe COVID-19, which is in alignment with prior published data. Regarding the clinical characteristics of patients with severe COVID-19, GRASSELLI et al. [11] reported that 82% of patients hospitalised in Italian hospitals were male, with a median age of 63 years, and frequently had several comorbidities. XIE et al. [10] reported that severely ill patients in China had a median age of 63 years; 65% were male and had a past medical history of cardiovascular diseases, specifically hypertension. Moreover, several studies have also confirmed the associations between age, sex and comorbidities and severe COVID-19 disease [2, 3, 18, 19]. Our findings are in concordance with our results, where the median admission age was 67.5 years, and the majority of patients were male. We also found that most patients who developed severe COVID-19 had at least one comorbidity, with hypertension, chronic cardiac diseases and chronic pulmonary diseases being most frequent.

During the pandemic, several pharmacological and nonpharmacological interventions have been used to treat patients with COVID-19 [5, 6, 20]. The primary approach was to identify effective treatments by

| TABLE 3 | Patients with severe coronavirus disease 2019 who developed complications stratified by patients admitted to the intensive care unit (ICU) |
|-----------------|-----------------|-----------------|-----------------|
| **Patients, n** | All  | Patients admitted to the ICU  | p-value |
| **Neurological, n (%)** | | | |
| Seizures | 393 (1.0) | 240 (1.2) | 153 (0.8) | <0.0001 |
| Stroke | 489 (1.2) | 281 (1.4) | 208 (1.0) | <0.0001 |
| Meningitis or encephalitis | 113 (0.3) | 93 (0.5) | 20 (0.1) | <0.0001 |
| Other neurological complications | 490 (1.2) | 228 (1.1) | 262 (1.3) | 0.19 |
| **Cardiovascular, n (%)** | | | |
| Congestive heart failure | 1183 (2.9) | 432 (2.2) | 751 (3.7) | <0.0001 |
| Endocarditis, myocarditis, pericarditis | 223 (0.6) | 191 (1.0) | 32 (0.2) | <0.0001 |
| Cardiac arrhythmia | 2992 (7.4) | 1995 (10.0) | 997 (4.9) | <0.0001 |
| Cardiac arrest | 1457 (3.6) | 1012 (5.0) | 445 (2.2) | <0.0001 |
| Cardiac ischaemia | 556 (1.4) | 303 (1.5) | 253 (1.2) | 0.021 |
| Cardiomyopathy | 195 (0.5) | 138 (0.7) | 57 (0.3) | <0.0001 |
| Myocardial infarction | 34 (0.1) | 31 (0.2) | 3 (0.0) | <0.0001 |
| **Pulmonary, n (%)** | | | |
| Bacterial pneumonia | 4695 (11.6) | 2591 (12.9) | 2104 (10.3) | <0.0001 |
| Acute respiratory distress syndrome | 7928 (19.6) | 5747 (28.7) | 2181 (10.7) | <0.0001 |
| Pneumothorax | 555 (1.4) | 447 (2.2) | 108 (0.5) | <0.0001 |
| Pleural effusion | 2198 (5.4) | 1093 (5.5) | 1105 (5.4) | 0.89 |
| Pulmonary embolism | 272 (0.7) | 237 (1.2) | 35 (0.2) | <0.0001 |
| Cryptogenic organising pneumonia | 122 (0.3) | 95 (0.5) | 27 (0.1) | <0.0001 |
| **Gastrointestinal, n (%)** | | | |
| Pancreatitis | 138 (0.3) | 103 (0.5) | 35 (0.2) | <0.0001 |
| Liver dysfunction | 2385 (5.9) | 1703 (8.5) | 682 (3.3) | <0.0001 |
| Gastrointestinal haemorrhage | 393 (1.0) | 221 (1.1) | 172 (0.8) | 0.008 |
| **Renal, n (%)** | | | |
| Acute kidney injury | 6566 (16.2) | 4030 (20.1) | 2536 (12.4) | <0.0001 |
| **Metabolic, n (%)** | | | |
| Hyperglycaemia | 3232 (8.0) | 2265 (11.3) | 967 (4.7) | <0.0001 |
| Hypoglycaemia | 757 (1.9) | 355 (1.8) | 402 (2.0) | 0.14 |
| **Haematological, n (%)** | | | |
| Anaemia | 5057 (12.5) | 3203 (16.0) | 1854 (9.1) | <0.0001 |
| Disseminated intravascular coagulation | 1296 (3.2) | 844 (4.2) | 452 (2.2) | <0.0001 |
| Bleeding | 84 (0.2) | 80 (0.4) | 4 (0.0) | <0.0001 |
| **Others, n (%)** | | | |
| Other complication | 6321 (15.6) | 2883 (14.4) | 3438 (16.9) | <0.0001 |
| Bacteraemia | 1848 (4.6) | 1366 (6.8) | 482 (2.4) | <0.0001 |
| Rhabdomyolysis or myositis | 246 (0.6) | 185 (0.9) | 61 (0.3) | <0.0001 |

https://doi.org/10.1183/23120541.00552-2021
Patients admitted to the intensive care unit (ICU) have lower cumulative deaths over time. a) The cumulative number of cases included in the study, stratified by b) patients admitted to the ICU and c) patients who were not admitted to the ICU. Proportions of patients still hospitalised at the moment of data extraction, discharged alive and reported dead are shown.
repurposing antiviral agents, immunomodulatory drugs and medications with theoretical antiviral properties. However, this approach led to excessive use of interventions without evidence-based support, and the data supporting these interventions are controversial [12, 21]. To date, the only medications that have been consistently demonstrated to reduce fatality ratios in COVID-19 patients requiring oxygen supplementation are corticosteroids, specifically dexamethasone [22, 23]. In our study, patients received several medications and non-pharmacological interventions. Notably, we found that most patients were treated with systemic antibiotics and many other interventions, as reported previously in other studies [24]. This high antibiotic usage in patients with severe COVID-19 is concerning, because bacterial co-infection was not frequent in our cohort. Moreover, it is essential to highlight that only 28.3% of patients were treated with systemic corticosteroids, being more frequently used in patients admitted to the ICU.

![Graphs showing marginal 28-day mortality rate (%)](image)

**FIGURE 4** Estimation of the non-linear effect on 28-day fatality ratio using a generalised additive model in patients with severe coronavirus disease 2019 (COVID-19) stratified by intensive care unit (ICU) admission. a) Age is shown to be an essential factor for higher fatality ratio in patients with severe COVID-19; however, patients admitted to the ICU have a lower fatality ratio independent of age. Even after adjusting by b) the number of new cases per million at the moment of hospital admission and c) the interaction over time, the marginal 28-day fatality ratio was lower in patients admitted to the ICU.

**TABLE 4** Generalised additive model fitted to assess the association of being admitted to the intensive care unit (ICU) with 28-day fatality ratio

| OR (95% CI)       | Estimated marginal mean (range) | p-value |
|--------------------|---------------------------------|---------|
| ICU admission      | 0.70 (0.65–0.75)                | <0.0001 |
| High-flow nasal cannula | 1.05 (1.00–1.11)               | 0.052   |
| Noninvasive respiratory support | 1.37 (1.31–1.44)              | <0.0001 |
| Invasive mechanical ventilation | 1.97 (1.81–2.14)            | <0.0001 |
| Vasopressors or inotropes     | 1.56 (1.44–1.70)              | <0.0001 |
| Number of comorbidities    | 1.07 (1.06–1.09)               | <0.0001 |
| Temperature on hospital admission | 0.92 (0.90–0.94)          | <0.0001 |
| Heart rate on hospital admission | 1.01 (1.00–1.01)           | <0.0001 |
| Respiratory rate on hospital admission | 1.03 (1.02–1.03)       | <0.0001 |
| Systolic blood pressure on hospital admission | 1.00 (1.00–1.01)      | <0.0001 |
| Diastolic blood pressure on hospital admission | 0.99 (0.99–0.99)     | <0.0001 |
| Acute respiratory distress syndrome | 1.47 (1.39–1.56)         | <0.0001 |
| Male               | 1.25 (1.19–1.31)               | <0.0001 |
| Month of hospital admission | 0.98 (0.96–0.99)           | <0.0001 |
| New cases per million | 1.00 (1.00–1.00)            | <0.0001 |

**Age (years)**

|   | 20 | 40 | 60 | 80 |
|---|----|----|----|----|
|   | 7.1% (5.8–8.7%) | 9.1% (8.3–9.9%) | 19.8% (19.0–20.6%) | 51.8% (50.7–52.9%) |

https://doi.org/10.1183/23120541.00552-2021
This might be explained by the fact that the RECOVERY trial results were published 6 months after the beginning of the pandemic [23, 25], and pre-pandemic data did not support the use of corticosteroids by many international guidelines in patients with severe viral pneumonia [26, 27].

The COVID-19 pandemic has brought unprecedented challenges to healthcare systems around the world [28]. In many countries, ICU capacity was overwhelmed, requiring severely ill patients to be treated in non-ICU settings [8, 9]. Other studies have evaluated the utility of using noninvasive respiratory support in the general wards, showing that this treatment can be safely delivered outside of the ICU [8], although outcomes were not compared with similar patients treated in an ICU. We found that treating patients in the ICU was associated with a lower fatality ratio after adjusting for a number of possible confounders, including the severity of illness. There is an important selection bias of patients admitted to ICU because clinicians tend to admit patients with a better survival probability. However, our results build on previous work that personnel trained in ICU care and the presence of a higher nurse-to-patient ratio may significantly impact the fatality ratio in severely ill patients more than access to specific organ support interventions [29].

An interpretation regarding why the fatality ratio is different among patients admitted or not to the ICU is required. These data are novel and have not been reported previously in patients with severe COVID-19. However, in Hong Kong, during the SARS 2003 pandemic, it was reported that expanding ICU settings was associated with higher fatality ratios [30]. Intensive care is often defined by the nurse-to-patient ratio and monitoring by trained staff, which may be a determinant of our findings [31]. Notably, we do not have information regarding personnel training, the monitoring systems used or the staff ratios caring for these patients.

Our study has strengths and limitations that are important to acknowledge. First, the ISARIC COVID-19 dataset is composed mainly of patients enrolled in high-income countries. However, this is a large prospectively collected cohort of patients enrolled in >40 countries worldwide, strengthening the generalisability of these results. We performed a sensitivity analysis which showed no difference across income groupings. Second, the decision not to admit a patient to the ICU may be based on several factors, including treatment restriction orders and the clinician’s estimation of survival; however, this information is not easily collected and was not available in our dataset. Not having these data limits the conclusions that may be drawn about the impact of ICU admission on clinical outcomes as it is a residual selection bias. Third, the definitions of what constituted an ICU varies per country and centre. We assumed that similar treatment and care were offered to all COVID-19 patients upon ICU admission. Notably, the identified protective effect of ICU admission was consistent in the entire cohort, even after sensitivity analyses. Fourth, several variants have emerged during the pandemic in different parts of the world. These variants have different disease severities, and vaccines might have different protective effects, affecting overall mortality. However, we did not have information regarding the virus identified, and thus, we did not control for this, which is an important limitation. However, we did control for admission date, which might indirectly control for these variables that appeared worldwide over the pandemic. Fifth, oxygen saturation and blood arterial gases are frequently used to determine severity and guide treatment in patients with COVID-19. However, in our study, we do not have these data in all patients, which is a limitation we need to recognise. Importantly, we have vital signs and systemic complications that allowed us to assess disease severity. Finally, as our study included patients from several countries and centres with high caseloads and resourced limitations, the analysis was limited by missing data, possibly biasing the ultimate results.

Conclusions

More than 30% of hospitalised SARS-CoV-2-infected patients develop severe COVID-19, with high fatality ratios. These patients frequently require advanced supportive treatments, which has imposed an unprecedented burden on healthcare systems worldwide. Providing high-quality care to severely ill patients is a complex endeavour that requires trained personnel, a designated setting, monitoring equipment and specialised management. The results presented in this study warrant caution about treating severely ill patients outside of an ICU and encourage hospitals to find strategies for severely ill patients to be treated in an ICU by personnel trained for the role.

Provenance: Submitted article, peer reviewed.

Acknowledgements: This work uses data or material provided by patients and collected by the National Health Service as part of their care and support. The data/material used for this research were obtained from ISARIC4C. The COVID-19 Clinical Information Network data were collated by ISARIC4C Investigators. This work was possible
due to the dedication and hard work of the Norwegian SARS-CoV-2 study team; the Groote Schuur Hospital COVID Intensive Care Unit Team, supported by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; and supported by the COVID clinical management team, AIMS, Rishikesh, India.

ISARIC Clinical Characterisation Group: Conceptualisation (this analysis): Reyes, Luis Felipe; Murthy, Srinivas; Garcia-Gallo, Esteban; Irvine, Mike; Merson, Laura; Martin-Loeches, Ignacio; Rello, Jordi; Taccone, Fabio S.; Webb, Steve A.; Fowler, Robert A.; Docherty, Annemarie B; Donnelly, Christl A.; Kartsonaki, Kristianna; Aragao, Irene; Barrett, Peter W.; Beane, Abigail; Broadley, Tessa; Cheng, Matthew Pellman; Christian, Michael D.; Cidade, Jose Pedro; Citarella, Barbara Wanjuji; Fernandes, Susana; Haniffa, Rashan; Harrison, Ewen M.; Ho, Antonia Ying Wai; Joseph, Mark; Khan, ifran; Kho, Michelle E; Kildal, Anders Benjamin; Kutsogiannis, Demetrios; Lamontagne, François; Lee, Todd C.; Li Bassi, Gianluigi; Lopez Revilla, Jose Wagner; Marquis, Catherine; Millar, Jonathan; Neto, Raul; Nichol, Alistair; Olliaro, Pier L.; Parke, Rachael; Pereira, Rui; Poli, Sergio; Povoa, Pedro; Ramanathan, Kollengode; Rello, Jordi; Rewa, Oleksa; Riera, Jordi; Rojek, Amanda; Sharpenel, Sally; Silva, Maria Joao; Trapani, Tony; Uy, Andrew; Uyeki, Timothy; Wils, Evert-Jan. Methodology: Reyes, Luis Felipe; Garcia-Gallo, Esteban; Murthy, Srinivas; Irvine, Mike. Review and editing: all authors. Data contributors, including the dedication and hard work of the Norwegian SARS-CoV-2 study team; the Groote Schuur Hospital COVID Intensive Care Unit Team, supported by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; and supported by the COVID clinical management team, AIMS, Rishikesh, India.

 ISARIC Clinical Characterisation Group: Conceptualisation (this analysis): Reyes, Luis Felipe; Murthy, Srinivas; Garcia-Gallo, Esteban; Irvine, Mike; Merson, Laura; Martin-Loeches, Ignacio; Rello, Jordi; Taccone, Fabio S.; Webb, Steve A.; Fowler, Robert A.; Docherty, Annemarie B; Donnelly, Christl A.; Kartsonaki, Kristianna; Aragao, Irene; Barrett, Peter W.; Beane, Abigail; Broadley, Tessa; Cheng, Matthew Pellman; Christian, Michael D.; Cidade, Jose Pedro; Citarella, Barbara Wanjuji; Fernandes, Susana; Haniffa, Rashan; Harrison, Ewen M.; Ho, Antonia Ying Wai; Joseph, Mark; Khan, ifran; Kho, Michelle E; Kildal, Anders Benjamin; Kutsogiannis, Demetrios; Lamontagne, François; Lee, Todd C.; Li Bassi, Gianluigi; Lopez Revilla, Jose Wagner; Marquis, Catherine; Millar, Jonathan; Neto, Raul; Nichol, Alistair; Olliaro, Pier L.; Parke, Rachael; Pereira, Rui; Poli, Sergio; Povoa, Pedro; Ramanathan, Kollengode; Rello, Jordi; Rewa, Oleksa; Riera, Jordi; Rojek, Amanda; Sharpenel, Sally; Silva, Maria Joao; Trapani, Tony; Uy, Andrew; Uyeki, Timothy; Wils, Evert-Jan. Methodology: Reyes, Luis Felipe; Garcia-Gallo, Esteban; Murthy, Srinivas; Irvine, Mike. Review and editing: all authors. Data contributors, including
Silva, Catarina; Silva, Maria Joao; Silva, Rogério; Sin, Wai Ching; Skogen, Vegard; Smith, Sue; Smed, Benjamin; Smyth, Michelle; Snacken, Morgane; So, Dominic; Solis, Monserrat; Solomon, Joshua; Solomon, Tom; Somers, Emily; Sommet, Agnès; Song, Myung Jin; Song, Rima; Song, Tae; Sonntagbauer, Michael; Soum, Edouard; Sousa, Ana Chora; Sousa, Marta; Sousa Uva, Maria; Souza-Dantas, Vicente; Sperry, Alexandra; Sr Darshana, B.P. Sanka Ruwan; Sriskandaran, Shiranee; Stabler, Sarah; Staudinger, Thomas; Stecher, Stephanie-Susan; Stienstra, Ymke; Stiksrud, Birgitte; Streinu-Cercel, Anca; Streinu-Cercel, Adrian; Strudwick, Samantha; Stuart, Ami; Stuart, David; Suen, Jacky Y.; Suen, Gabriel; Suntana, Asila; Summers, Charlotte; Surovcová, Magdalena; Synigos, Konstantinos; Sztabnik, Jakues; Szuldzynski, Konstanty; Tabrizi, Shirin; Taccone, Fabio; Tagheriset, Lysa; Taleb, Sara; Talsma, Jelmer; Tan, Le Van; Tanaka, Hiroiuki; Tanaka, Taku; Taniguchi, Hayato; Tanveer, Hussain; Tardivon, Coralie; Tattevin, Pierre; Taufik, M. Azhari; Tedder, Richard S.; Teixeira, João; Tejada, Sofia; Tellier, Marie-Capucine; Teotonio, Vanessa; Téoulié, François; Terpstra, Pleun; Terrier, Olivier; Terzi, Nicolas; Tessler-Grenier, Hubert; Thibault, Vincent; Thill, Benoît; Thompson, Shana; Thomson, Emma C.; Thomson, David; Thuy, Duong Binh; Thwaites, Ryan S.; Timsit, Jean-François; Tirupakuzhi Vijayaraghvan, Bharath Kumar; Tissot, Noémie; Toki, Maria; Tolppa, Timo; Tonby, Kristian; Torres, Antoni; Torres-Zevallos, Hernando; Trapani, Tony; Treoux, Théo; Truong, Huynh Trung; Tromeur, Cécile; Trontzas, Ioannis; Troost, Jonathan; Treuillon, Tiffany; Truong, Jeanne; Tual, Christelle; Tubiana, Sarah; Tuine, Lance C.W.; Twadowski, Pawel; Uchiyama, Makoto; Udayangay, P.G. Ishara; Udy, Andrew; Ulrich, Roman; Uribe, Alberto; Usman, Asad; Val-Flores, Luis; Valran, Amélie; Van De Velde, Stijn; van den Berge, Marcel; Van der Feltz, Machteld; Van Der Vekens, Nicky; Van der Voort, Peter; Van Der Werf, Sylvie; van Gulik, Laura; Van Hattem, Jarne; van Lelyveld, Steven; van Netten, Carolien; van Twillert, G; Vanel, Noémie; Vanoverschelde, oHenk; Vauchy, Charline; Veislinger, Aurélie; Ventura, Sara; Verbon, Annelies; Vidal, José Ernesto; Vieira, César; Villanueva, Joy Ann; Villar, Judit; Villeneuve, Pierre-Marc; Villoldo, Andrea; Vinh Chau, Nguyen Van; Visseaux, Benoit; Visser, Hannah; Vitiello, Chiara; Vootto, Fanny; Wang, Chih-Hsien; Wei, Jia; Weil, Katharina; Wesselinus, Sanne; Wham, Murray; Whelan, Bryan; White, Nicole; Wicky, Paul Henri; Wiedemann, Aurélie; Wille, Keith; Williams, Virginie; Wils, Evert-Jan; Wolf, Timo; Xynogalas, Ioannis; Yacoub, Sophie; Yamazaki, Masaki; Yazdanpanah, Yazdan; Yelnik, Cécile; Yerkovich, Stephanie; Yokoyama, Toshiki; Yonis, Hodane; Yuliarto, Sapta; Zaaqoq, Akram; Zabbe, Marion; Zacharowski, Kai; Zahran, Maram; Zambrano, Miguel; Zanella, Alberto; Zoufaly, Alexander; Zucman, David.

Data sharing: The dataset is available from the Infectious Disease Data Observatory website (https://www.iddo.org).

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of this manuscript. The corresponding author (LFR) had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Conflict of interest: L.F. Reyes has nothing to disclose. S. Murthy declares receiving salary support from the Health Research Foundation and Innovative Medicines Canada Chair in Pandemic Preparedness Research. E. Garcia-Gallo has nothing to disclose. M. Irvine has nothing to disclose. L. Merson has nothing to disclose. I. Martin-Loeches declares consulting fees for Gilead outside of the submitted work. J. Rello has nothing to disclose. F.S. Taccone has nothing to disclose. R.A. Fowler has nothing to disclose. A.B. Docherty has nothing to disclose. C. Kartsonaki has nothing to disclose. I. Aragao has nothing to disclose. P.W. Barrett has nothing to disclose. A. Bean has nothing to disclose. A. Burrell has nothing to disclose. M.P. Cheng has nothing to disclose. M.D. Christian has nothing to disclose. J.P. Cidade has nothing to disclose. B.W. Citarella has nothing to disclose. C.A. Donnelly has nothing to disclose. A.B. Kildal has nothing to disclose. D. Kutsogiannis declares personal fees for a lecture from Tabuk Pharmaceuticals and the Saudi Critical Care Society. F. Lamontagne has nothing to disclose. T.C. Lee declares research salary support from les Fonds de recherche du Québec – Santé. G.L. Bassi has nothing to disclose. A.B. Kildal has nothing to disclose. D. Kutsogiannis declares personal fees for a lecture from Tabuk Pharmaceuticals and the Saudi Critical Care Society. F. Lamontagne has nothing to disclose. T.C. Lee declares research salary support from les Fonds de recherche du Québec – Santé. G.L. Bassi has nothing to disclose. J.W. Lopez Revilla has nothing to disclose. C. Marquis has nothing to disclose. J. Millar has nothing to disclose. R. Neto has nothing to disclose. A. Nichol declares a grant from the Health Research Board of Ireland to support data collection in Ireland (CTN-2014-012). R. Parke has nothing to disclose. R. Pereira has nothing to disclose. S. Poli has nothing to disclose. P. Povoa declares personal fees (for lectures and advisory boards) from MSD, Technophage, Sanofi and Gilead. K. Ramanathan has nothing to disclose. O. Rewa declares consulting fees from Baxter Inc. J. Riera has nothing to disclose. S. Shrapnel participated as an investigator for an observational study analysing intensive care unit patients with COVID-19 (for the Critical Care Consortium including ECMOCARD) funded by The Prince Charles Hospital Foundation during the conduct of this study. S. Shrapnel reports in kind support from the Australian Research Council Centre of Excellence for Engineered Quantum Systems (CE170100009). M.J. Silva has nothing to disclose. A. Udy has nothing to disclose. T. Uyeki has nothing to disclose.
S.A. Webb has nothing to disclose. E.J. Wils has nothing to disclose. A. Rojek has nothing to disclose. P.L. Olliaro has nothing to disclose.

Support statement: This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome (215091/Z/18/Z), the Bill and Melinda Gates Foundation (OPP1209135), Canadian Institutes of Health Research Coronavirus Rapid Research Funding Opportunity OV2170359, grants from Rapid European COVID-19 Emergency Response Research (Horizon 2020 project 101003589), the European Clinical Research Alliance on Infectious Diseases (96533), The Imperial National Institute for Health Research (NIHR) Biomedical Research Centre, and The Cambridge NIHR Biomedical Research Centre; and endorsed by the Irish Critical Care Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland (CTN-2014-12). Data and Material provision was supported by grants from: the NIHR (award CO-CIN-01), the Medical Research Council (grant MC_PC_19059), the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) (award 200907), Wellcome Trust (Turtle, Lance-fellowship 205228/Z/16/Z), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. This work was by Research Council of Norway grant number 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner. Funding information for this article has been deposited with the Crossref Funder Registry.

References
1 Richards-Belle A, Orzechowska I, Gould DW, et al. COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. Intensive Care Med 2020; 46: 2035–2047.
2 Sinha P, Caf Lee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med 2020; 8: 1209–1218.
3 Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care 2020; 24: 285.
4 Rodríguez A, Ruiz-Botella M, Martín-Loeches I, et al. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit Care 2021; 25: 63.
5 Coopersmith CM, Antonelli M, Bauer SR, et al. The Surviving Sepsis campaign: research priorities for coronavirus disease 2019 in critical illness. Crit Care Med 2021; 49: 598–622.
6 Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomised clinical trials during pandemics. JAMA 2020; 323: 1897–1898.
7 Wu G, Yang P, Xie Y, et al. Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study. Eur Respir J 2020; 56: 2001104.
8 Franco C, Facciolongo N, Tonelli R, et al. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. Eur Respir J 2020; 56: 2002130.
9 Aziz S, Arabi YM, Alhazzani W, et al. Managing ICU surge during the COVID-19 crisis: rapid guidelines. Intensive Care Med 2020; 46: 1303–1325.
10 Xie J, Wu W, Li S, et al. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med 2020; 46: 1863–1872.
11 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323: 1574–1581.
12 Azoulay E, de Waele J, Ferrer R, et al. International variation in the management of severe COVID-19 patients. Crit Care 2020; 24: 486.
13 Our World in Data. Coronavirus (COVID-19) Cases. https://ourworldindata.org/covid-cases/ 2020. Date last accessed: 12 April 2021.
14 Ranzani OT, Bastos LSL, Gelli JGM, et al. Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med 2021; 9: 407–418.
15 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475–481.
16 Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med 2020; 46: 2200–2211.
17 Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalised with COVID-19 in the New York City area. JAMA 2020; 323: 2052–2059.
18 COVID-ICU Group on behalf of the REVA network and the COVID-ICU investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. *Intensive Care Med* 2021; 47: 60–73.

19 Gupta RK, Harrison EM, Ho A, et al. Development and validation of the ISARIC 4C deterioration model for adults hospitalised with COVID-19: a prospective cohort study. *Lancet Respir Med* 2021; 9: 349–359.

20 Waterer GW, Rello J, Wunderink RG. COVID-19: first do no harm. *Am J Respir Crit Care Med* 2020; 201: 1324–1325.

21 Angus DC. Optimising the trade-off between learning and doing in a pandemic. *JAMA* 2020; 323: 1895–1896.

22 Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA* 2020; 324: 1330–1341.

23 Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalised patients with Covid-19. *N Engl J Med* 2021; 384: 693–704.

24 Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect* 2020; 26: 1622–1629.

25 Águas R, Mahdi A, Shretta R, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. *Nat Commun* 2021; 12: 915.

26 Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019; 200: e45–e67.

27 Moreno G, Rodríguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. *Intensive Care Med* 2018; 44: 1470–1482.

28 Grasselli G, Pesenti A, Cecconi M. Critical care utilisation for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. *JAMA* 2020; 323: 1545–1546.

29 McHugh MD, Aiken LH, Sloane DM, et al. Effects of nurse-to-patient ratio legislation on nurse staffing and patient mortality, readmissions, and length of stay: a prospective study in a panel of hospitals. *Lancet* 2021; 397: 1905–1913.

30 Gomersall CD, Tai DY, Loo S, et al. Expanding ICU facilities in an epidemic: recommendations based on experience from the SARS epidemic in Hong Kong and Singapore. *Intensive Care Med* 2006; 32: 1004–1013.

31 Shrestha GS, Kwisera A, Lundeg G, et al. International Surviving Sepsis campaign guidelines 2016: the perspective from low-income and middle-income countries. *Lancet Infect Dis* 2017; 17: 893–895.